Advertisement

Topics

Advent International enters into exclusive negotiations to acquire Zentiva, Sanofi's European generics business

04:30 EDT 17 Apr 2018 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
  Press ReleaseSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Advent International enters into exclusive negotiations to acquire Zentiva, Sanofi's European generics business Advent to invest in Zentiva to create a n...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Advent International enters into exclusive negotiations to acquire Zentiva, Sanofi's European generics business"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Sanofi-Aventis
Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health problems, their major products are those for diabetes, o...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...